tradingkey.logo

MiMedx Group Inc

MDXG
View Detailed Chart

7.150USD

+0.210+3.03%
Close 09/18, 16:00ETQuotes delayed by 15 min
1.06BMarket Cap
32.87P/E TTM

MiMedx Group Inc

7.150

+0.210+3.03%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.03%

5 Days

+3.77%

1 Month

+0.56%

6 Months

-11.07%

Year to Date

-25.68%

1 Year

+16.26%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
5 / 507
Overall Ranking
61 / 4723
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
12.200
Target Price
+75.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.26% year-on-year.
Overvalued
The company’s latest PE is 31.76, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 106.45M shares, decreasing 3.61% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.93M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Ticker SymbolMDXG
CompanyMiMedx Group Inc
CEOMr. Joseph H. (Joe) Capper
Websitehttps://mimedx.com/
KeyAI